Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06732596 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Sustaining Recovery for People on Opioid Agonist Treatment With Conversational Agents

Study acronym: SARA RCT
StatusRecruiting
PhaseNot applicable
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Eligibility criteria expanded, about 10 words
    • Secondary endpoints: details revised at 7 of 8 entries
  2. Trial status: Not Yet Recruiting to Recruitingv10 Show 5 more changesShow less
    • Start date changed from estimate of Oct 2025 to Oct 30, 2025
    • Eligibility criteria shortened, about 17 words
    • Study description expanded, about 7 words
    • Site details revised
    • Study arms: 4 to 2
  3. Start date: Sep 2025 to Oct 2025v9
  4. Start date: Aug 2025 to Sep 2025v8
  5. Eligibility criteria shortened, about 20 words
    • Site contact updated
    v7
Show 5 earlier versionsHide 5 earlier versions
  1. Start date: Jul 2025 to Aug 2025v6
  2. Start date: Jun 2025 to Jul 2025v5
  3. Start date: May 2025 to Jun 2025v4
  4. Start date: Feb 2025 to May 2025
    • Primary and study completion dates: Aug 2026 to Dec 2026
    v3
  5. Start date: Jan 2025 to Feb 2025v2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This study aims to improve retention in buprenorphine treatment, a medication used for opioid use disorder, through the use of a smartphone-delivered recovery support intervention. The intervention involves an Embodied Conversational Agent (ECA), a virtual, animated computer agent designed to simulate natural face-to-face conversations. ECAs have been shown to help individuals manage their healthcare in other settings, and this study seeks to evaluate their potential in supporting patients on medication for opioid use disorder (MOUD).
Trial Details
NCT Number NCT06732596
Lead Sponsor Boston Medical Center
Collaborators: National Institute on Drug Abuse (NIDA)
Conditions
(from sponsor)		 Opioid Use Disorder
Related terms Opioid-Related Disorders
Enrollment 100 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov